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A b s t r a c t
Introduction: Patients with peripheral artery disease (PAD) are considered as a high-risk group for hemorrhagic events. 
Aim: To assess the safety of bivalirudin vs. unfractionated heparin (UFH) in percutaneous peripheral interventions (PPI) in short- 
and long-term follow-up.
Material and methods: The retrospective single-center, observational study included 160 patients, undergoing PPI. Patients 
were divided into 2 groups based on the use of anticoagulation – unfractionated heparin (UFH group) or bivalirudin (Biv. group) – 
and observed up to 5 years.
Results: The UFH group consisted of 101 patients and the Biv. group consisted of 59. We registered the following end points 
during in-hospital observation: 1 death (0.63% Biv, p = 0.18), 12 hematomas at puncture site (0.63% Biv. vs. 7.05% UFH, p = 0.04), 
2 pseudoaneurysms (1.27% UFH, p = 0.29), thrombosis (0.63% UFH, p = 0.45), 1 bleeding from puncture site (0.63% UFH, p = 0.45). 
The total number of hemorrhagic complications was 1.24% in the Biv. group and 8.07% in the UFH group (p = 0.04). During long-
term follow-up of 65.7 ±36.4 months the all-cause mortality rate was higher in the Biv. group (8.59% Biv vs. 0% in UFH group, 
p = 0.009). Regression analysis showed that bivalirudin administration is a  risk factor for increased mortality risk (p = 0.003, 
OR = 15, 95% CI: 3.3–107.8).
Conclusions: Usage of UFH was associated with a higher number of hemorrhagic complications, especially hematomas at the 
puncture site in comparison to patients receiving bivalirudin.
Key words: bivalirudin, heparin, peripheral artery disease, long-term mortality.
S u m m a r y
In patients undergoing peripheral vascular interventions bivalirudin can be a valid option for anticoagulation during pro-
cedure. Impact of bivalirudin on decreased number of bleeding complications and low risk of thromboembolic events, can 
translate to increased safety of percutaneous peripheral interventions and can reduce cost of hospitalization and ambulatory 
care of patients with peripheral artery disease.
Introduction
Bivalirudin is an anticoagulant drug, a  reversible di-
rect thrombin inhibitor, used mostly in percutaneous cor-
onary interventions (PCI) [1]. The pharmacological profile 
with a short half-life (around 25 min) makes bivalirudin 
an option for patients with a  contradiction for unfrac-
tionated heparin (UFH) or high risk of bleeding [1, 2]. Pa-
tients with peripheral artery disease (PAD) can usually be 
considered as a high-risk group for hemorrhagic events 
[3]. According to ESC guidelines bivalirudin can be used 
as the primary anticoagulation in patients with a histo-
ry of heparin-induced thrombocytopenia [4–6]. Due to 
the reported lower bleeding complication rate compared 
to UFH in patients with high risk of hemorrhagic it is 
worth considering bivalirudin administration [4]. Also, 
in patients with non-ST-elevation myocardial infarction 
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(NSTEMI) bivalirudin is an alternative to UFH adminis-
tered combined with GP IIb/IIIa during PCI [5]. Nowadays, 
indications for bivalirudin are well defined in guidelines 
for coronary interventions, but there is still a lack of ran-
domized trials focused on anticoagulation during periph-
eral procedures [6].
Aim
Thus, we aimed to investigate the safety of bivali-
rudin vs. UFH in percutaneous peripheral interventions 
(PPI) in short- and long-term follow-up, especially risk of 
bleeding and thromboembolic complications and major 
cardiovascular and peripheral events. 
Material and methods
In our retrospective single-center, observational study 
all data were gathered between 2006 and 2014. One hun-
dred sixty-one patients who underwent PPI were includ-
ed. The study included patients who underwent differ-
ent types of PPI: in carotid arteries, in arteries above the 
knee, in arteries below the knee, in subclavian arteries. 
We excluded patients after PPI of renal arteries, arterio-
venous fistula, in-stent restenosis or with chronic total 
occlusion. Patients with acute limb ischemia or qualified 
for surgery of peripheral artery disease were excluded 
from the study (Figure 1).
Patients were divided into two groups according to 
the anticoagulant used during PPI: unfractionated hepa-
rin (UFH group) or bivalirudin (Biv. group). Baseline clini-
cal data were assessed. Before the index procedure rou-
tine laboratory tests were performed. Procedures were 
performed in compliance with a  standardized institu-
tional protocol. Dosage of UFH was adjusted to patients’ 
weight. Bivalirudin was administered as a bolus before 
the PPI and continued as intravenous infusion during 
the procedure (0.75 mg/kg bolus and 1.75 mg/kg/h in-
fusion) under activated clotting time control. Procedures 
were performed with the antegrade technique. Vascular 
sheets were removed 4 h after the procedure and hemo-
stasis was achieved by manual compression. After the 
procedure and during in-hospital observation patients 
were assessed for major cardiovascular events (MACCE) 
such as all-cause mortality, myocardial infarction, stroke/
transient ischemic attack, urgent PCI or coronary artery 
bypass grafting; bleeding complications (classified ac-
cording to BARC criteria), and for major peripheral events 
(MAPE) such as vascular complications (bleeding from 
access site, thrombosis, hematoma, vessel perforation, 
arteriovenous fistula, pseudoaneurysm) and amputa-
tions. In long-term follow-up patients were observed for 
MACCE, rePPIs, amputations and deaths. The follow-up of 
the patients was conducted up to 5 years. Data from the 
Polish National Health Fund were used. 
All procedures performed in this study were in accor-
dance with the ethical standards and complied with the 
Declaration of Helsinki for medical research. 
Statistical analysis
Results were presented as number of patients (per-
centage), mean value with standard deviation (SD) or 
median with interquartile range (IQR), as appropriate. 
For dichotomous variables the c2 test and Fisher’s test 
were used. In the case of dichotomous variables, the 
Mann-Whitney U-test was used. The Kaplan-Meier meth-
od was used to assess the difference in mortality during 
follow-up between patients. Additionally, multivariable 
Figure 1. Plot: patient inclusion algorithm
Biv. – bivalirudin, PCI – percutaneous coronary intervention, PTA – percutaneous transluminal angioplasty, UFH – unfractionated heparin.
Patients excluded from the study:
–  with acute limb ischemia
–  qualified for surgery treatment of peripheral artery disease
–  with severe kidney failure
Patients with intermittent claudi-
cation admitted to cardiovascular 
department (n = 352)
Patients admitted due to angina and 
patients who underwent angiogra-
phy of coronary artery disease or PCI 
during index hospitalization (n = 126)
PTA of renal artery (n = 2)
PTA of arteriovenous fistula (n = 3)
Unsuccessful PTA (n = 10)
PTA of branchiocephalic trunk (n = 2)
PTA of chronic total occlusion (n = 21)
Retrograde technique of PTA (n = 17)
In stent restenosis (n = 10)
(n = 65)
Biv. group (n = 59) UFH group (n = 101)
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regression analysis (Cox’s regression) was performed to 
find predictors of long-term mortality. All tests were two-
tailed, and a p-value of < 0.05 was considered statistical-
ly significant. 
Results
We included 161 patients with established indica-
tions for PPI. The UFH group consisted of 102 patients 
(80% men), and the bivalirudin group (Biv. group) con-
sisted of 59 patients (76.2% men). Demographic data are 
shown in Table I. Mean age of patients was 65.4 ±7.2 
years in the Biv. group and 65.1 ±8.5 years in the UFH 
group. Rates of cardiovascular risk factors were similar 
between the groups except oral treatment of diabetes 
(in the UFH group it was higher, p = 0.01). Nineteen 
(32% in Biv. group) vs. 18 (17.8% in UFH group) percuta-
neous interventions in carotid arteries were performed; 
37 (62.7% Biv. group) vs. 75 (72% in UFH group) in arter-
ies above the knee, 2 (3.4% Biv. group) vs. 7 (6.9% UFH 
group) in arteries below the knee, and 1 in subclavian 
artery intervention (both groups). The most common ac-
cess site was the femoral artery: 31 (52.5%) in the Biv 
and 79 (49%) in the UFH group. 
In-hospital observation
Mean in-hospital stay was 7.3 ±4.8 (Biv) vs. 5.9 ±3.8 
(UFH) days (p = 0.06). One death in the Biv. group was 
registered (0.63% Biv, p = 0.18). We observed 12 hema-
tomas at the puncture site (0.63% Biv vs. 7.05% UFH, 
p = 0.04), 2 pseudoaneurysms (1.27% UFH, p = 0.29), 
1 case of thrombosis (0.63% UFH, p = 0.45), and 1 case 
of bleeding from the puncture site (0.63% UFH, p = 0.45). 
Arteriovenous fistula, retroperitoneal bleeding and loss 
of limb were not observed during hospital observation. 
There were no statistically significant drops of hemo-
globin levels in any group (Table II). The total number of 
hemorrhagic complications was 1.24% in the Biv. group 
and 8.07% in the UHF group (p = 0.04, Table III). 
Long-term follow-up
Mean time of long-term follow-up was 65.7 ±36.4 
months. All-cause mortality was higher in the Biv. group 
(8.69%, vs. 7% in UFH group, p = 0.009; Figure 2). The 
repeated PPI rate was higher in the Biv. group (6.8% vs. 
11.8% in Biv. group). In the logistic regression model, 
with multiple independent variables bivalirudin adminis-
tration was associated with higher risk of all-cause mor-
tality than UFH (OR = 15. 95% CI: 3.3–107.8; Table III, 
Figure 2).
Discussion
Bivalirudin is a well-known anticoagulant, used during 
percutaneous procedures, especially coronary interven-
Table I. Demographic and clinical characteristics
Variable Biv. group % (n = 59) UFH group % (n = 102) P-value
Age [years] 65.42 65.14 0.95
Sex (male) 76.2% (45) 80% (81) 0.53
Coronary artery disease 88% (52) 92% (93) 0.99
PCI in past 40.6% (24) 48.5% (49) 0.47
CABG in past 11.8% (7) 8.9% (9) 0.46
History of PPI 25% (15) 40.1% (41) 0.10
History of CAS 1.7% (1) 5.9% (6) 0.23
DM: 30.5% (18) 34.6% (35)
Diet 6.7% (4) 1% (1) 0.03
Oral treatment 5.1% (3) 19.8% (20) 0.01
Insulin treatment 18.6% (11) 13.8% (14) 0.35
Hypertension 81% (48) 83% (84) 0.76
Hypercholesterolemia 79.6% (47) 86% (87) 0.3
Smoking 22% (13) 22.7% (23) 0.34
History of stroke 23.7% (14) 15.8% (16) 0.003
History of TIA 1.7% (1) 1.9% (2) 0.59
CABG – coronary artery bypass grafting, CAS – carotid artery stenting, DM – diabetes mellitus, PCI – percutaneous coronary intervention, PPI – percutaneous periph-
eral intervention, TIA – transient ischemic attack.
Joanna Wojtasik-Bakalarz et al. Bivalirudin vs. UFH during peripheral interventions
94 Advances in Interventional Cardiology 2019; 15, 1 (55)
tions [1]. We confirmed a  lower rate of periprocedural 
complications in bivalirudin with the rate of all in-hos-
pital complications at 1.24%, which makes our results 
favorable compared to already published data. Usage of 
bivalirudin was not associated with any ischemic events, 
such as stroke, acute coronary syndrome (ACS) or throm-
Table II. Laboratory tests before and after procedure
Parameter Biv. group % (n = 59) UFH group % (n = 101) P-value
Before PPI After PPI Before PPI After PPI
Hemoglobin level [g/dl] 15.8 ±0.5 12.23 ±2.37 13.75 ±1.53 12.06 ±2.05 0.2
Platelets level [× 1000/ml] 211.91 ±56.25 209.7 ±85 208.03 ±63.87 193.3 ±61.87 0.6
eGFR [ml/min/1.73 m2] 77.89 ±22.87 47 ±26 82.47 ±25.74 56.88 ±6.9 0.5
eGFR – estimated glomerular filtration rate.
Table III. In hospital complications, long-term follow-up data and results of regression analysis
Variable Biv. group % (n) UFH group % (n) P-value
In-hospital observation:
Death 0.63% (1) 0 0.18
Hematoma at puncture site 0.63% (1) 7% (11) 0.04
Pseudoaneurysm 0 1.27% (2) 0.29
Thrombosis in target artery 0 0.63% (1) 0.45
Bleeding from puncture site 0 0.63% (1) 0.45
All complications 1.24% (2) 8.07% (15) 0.04
Long-term follow-up:
PCI 13.2% (17) 37.5% (48) 0.28
CABG 1.56% (2) 0.78% (1) 0.17
Death (all-cause) 8.59% (11) 7% (8) 0.009
Stroke 0% 1.56% (2) 0.34
ACS 1.56% (2) 3.13% (4) 0.87
GIB 0 0
Heart failure 3.13% (4) 6.25% (8) 0.82
Kidney failure 0 0
Amputation 1.56% (2) 0.78% (1) 0.16
CAS 0.78% (1) 0 0.12
rePPI 11.8% (7) 6.86% (7)
Regression analysis (Cox’s regression)
Variable OR 95% CI P-value
Anticoagulation (bivalirudin) 15.02 3.3–107.8 0.0003*
ACS 0.3 0.06–1.67 0.2
PCI or CABG 1.2 0.2–5.6 0.79
Sex 1.3 0.2–6.7 0.7
Age 0.9 1.04–1.06 0.8
ACS – acute coronary syndrome, CABG – coronary artery bypass grafting, CAS – carotid artery stenting, GIB – gastrointestinal bleeding, PCI – percutaneous coronary 
intervention, rePPI – repeated percutaneous peripheral intervention.
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bosis during in-hospital observation. We reported one 
case of early thrombosis in the UFH group. However, 
long-term follow-up showed a  higher rate of deaths in 
the bivalirudin group (8.69% Bi, p = 0.0095). These data 
were confirmed in our long-term follow-up. It is difficult 
to discuss that results, due to lack of randomized trials 
or large reports about safety of bivalirudin in peripher-
al interventions. Therefore, we can only extrapolate the 
results from published trials in patients who underwent 
coronary angioplasty. 
In the REPLACE-2 trial (patients with stable CAD) the 
anticoagulant effect of bivalirudin combined with GP IIb/
IIIa was comparable to UFH combined with GP IIa/IIIa 
[7]. Based on the ISAR-REACT 3 trial, bivalirudin is asso-
ciated with a  lower rate of bleeding events in patients 
with stable CAD with no influence on mortality during 
observation [8]. Also, in the ACUITY study bivalirudin 
(in 7.4% cases with GP IIb/IIIa) versus UFH plus GP II/
IIIa inhibitors was favorable in combined ischemic and 
hemorrhagic complications in 30 days’ observation 
(p = 0.02). In hemorrhagic complications alone, this dif-
ference is more visible in 1-year observation (3.0% vs. 
5.7%; p < 0.001) [9]. The ISAR-REACT 4 study (patients 
with NSTEMI) showed a  low rate of serious bleeding 
events in the group of patients with bivalirudin (2.6% 
vs. 4.6% of UFH) [10]. The results of the HORIZONS-AMI 
study showed that treatment with bivalirudin (vs. UFH 
plus GP IIa/IIIa inhibitors) results in lower rates of car-
diac mortality (1.8%, p = 0.03) and all-causes deaths 
(2.1%, p = 0.047) in 30 days’ FU [11]. It also confirms 
reductions of major bleeding events in 1-year obser-
vation [11]. However, in the HORIZON-AMI study and 
EUROMAX study the problem of acute in-stent thrombosis 
was reported [11, 12]. Frequency of stent thrombosis was 
higher in the bivalirudin group than in the control group 
(1.6% vs. 0.5%; p = 0.02), with a  significant difference 
within the first 24 h and without a difference in subacute 
stent thrombosis at 30 days of follow-up [12]. Despite all 
these results, UFH iv is still a standard anticoagulant in 
PCI. In the Bravo-3 trial in patients with PAD and severe 
aortic stenosis, at 30 days of follow-up, use of bivaliru-
din during transcatheter aortic valve implantation was 
not associated with reduction of cardiovascular events 
or bleeding events [13]. Bivalirudin use nevertheless was 
associated with higher prevalence of acute kidney failure 
(p = 0.03) [13]. Pseudoaneurysms are common compli-
cations after artery puncture during endovascular proce-
dures. The frequency of femoral pseudoaneurysm varies 
between 0.5% after a  diagnostic coronary procedure 
and 8% after endovascular coronary interventions. Risk 
of this vascular complication is greater in patients with 
atherosclerosis, hypertension, obesity, or kidney failure 
[14–16]. We observed a  frequency of 1.27% for pseudo-
aneurysms after PPI in the group of patients treated with 
heparin and none in the bivalirudin group. Compared to 
results of patients after PCI treated with bivalirudin alone 
by Ormiston el al., hematoma occurred less frequently af-
ter PPI than after PCI – 2% vs. 0.63% in our research [17].
Though patients with coronary artery disease have 
the same risk factors as patients with PAD and percu-
taneous procedures have some similarities, it is worth 
pointing out that peripheral procedures are usually 
longer than PCI and result in a higher rate of bleeding 
complications, and the risk in patients with PAD is higher 
than in patients without PAD [3, 18]. That makes studies 
of PPI relevant and necessary. 
The bleeding risk in patients undergoing PPI of lower 
limb arteries associated with anticoagulant used during 
the procedure is not well defined. Abtahian et al. present-
ed comparable results of bleeding events in both groups 
during PCI. There were no differences between bivaliru-
din and UFH in risk of major bleeding (1.8% UFH vs. 2.4% 
bivalirudin, p = 0.305), or combined major and minor 
bleeding (4.3% for both). In-hospital observation also 
shows similar results for rates of death, MI or re-PCI [19]. 
In published studies bivalirudin seems to be a safe option 
for patients who underwent PPI. Rates of major ischemic 
and adverse bleeding events are low: cerebrovascular 
events (0.3%), acute renal failure (0.3%), major bleeding 
(0.8%), distal embolization (3.0%), access site complica-
tions (0.5%), minor amputation (0.5%) or bleeding event 
requiring red blood cell transfusions (0.9%, p = 0.01) [20]. 
According to Oritz et al., patients who underwent per-
cutaneous vascular interventions with bivalirudin usage 
have a lower rate of local bleeding complications (access 
site hematoma) (2.4% vs. 3.9%, p = 0.018) and shorter 
time of hospitalization (1.0 vs. 1.2 days, p  <  0.001) [21]. 
There are no differences in access site occlusion, distal 
embolization or mortality. A study by Shammas et al. re-
sulted in an overall complication rate of 4.2% with bivali-
rudin vs an event rate of 9.2% for UFH during PPI [22]. 
Figure 2. Kaplan-Meier curves for survival after 
percutaneous peripheral interventions stratified 
by the use of unfractionated heparin (UFH) or bi-
valirudin
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Sheikh et al. found no differences in procedural success 
or major and minor bleeding. In contrast to the results of 
Ortiz et al., Sheikh et al. and our study did not confirm 
reduction of length in hospital stay [23]. Moreover, the 
APPROVE trial defined predictors for bleeding events in 
patients treated with bivalirudin as the primary antico-
agulant, such as female gender, exchange to larger sheet 
and low weight (< 80 kg males, < 62 kg females). The 
study also showed a low rate of ischemic events, around 
1.4%, and a major hemorrhage rate at 2.2% [24]. In our 
study we did not confirm female gender as a risk factor 
for bleeding events. 
Unfortunately, information about long-term out-
comes of bivalirudin in patients undergoing peripheral 
vascular interventions are limited and trials focus only 
on 30-day follow-up. The safety profile of bivalirudin in 
the context of bleeding events is similar in published 
studies. The mechanisms through which bivalirudin in-
creased mortality in long-term follow-up are unknown 
and our collected data are insufficient to confirm the 
exact pathomechanism leading to the suggested high-
er risk of death. This topic should be further explored in 
randomized, preferably multicenter trials and confirmed 
in large-sample size studies.
Limitations of study
Our study has obvious limitations. It was non-ran-
domized, retrospective and single center, with a  rather 
small patient population. However, due to the lack of data 
on usage of bivalirudin in patients undergoing peripheral 
interventions, our study represents real-world data.
Conclusions
In patients undergoing peripheral vascular interven-
tions bivalirudin can be a valid option for anticoagulation 
during the procedure. The impact of bivalirudin on the de-
creased number of bleeding complications and low risk of 
thromboembolic events can translate to increased safety 
of PPIs and can reduce costs of hospitalization and am-
bulatory care of patients with peripheral artery disease. 
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